LONE TREE, Colo.–(BUSINESS WIRE)–Zynex, Inc. (OTCBB: ZYXI), a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announced the hiring of Keith White as Vice President of Reimbursement and Billing. Mr. White will start on September 19, 2011 and will report directly to Thomas Sandgaard, Chief Executive Officer.

“We believe Mr. White brings a tremendous amount of industry experience that will strengthen our management team and help us continue to improve and execute our successful reimbursement strategy.”

Mr. White has over 20 years of healthcare and senior management experience, specifically in the electrotherapy market space, and possesses an in-depth knowledge of the complex healthcare coding and reimbursement guidelines. Mr. White most recently served as President for Aquarius Water Conditioning, Inc., and spent 20 years in various management positions with Empi, Inc., a DJO Global Inc. company, including Director of Sales Operations and Patient Care Services and Billing. Empi, Inc. is a major electrotherapy company in the industry.

Thomas Sandgaard, CEO stated, “We believe Mr. White brings a tremendous amount of industry experience that will strengthen our management team and help us continue to improve and execute our successful reimbursement strategy.” Mr. Sandgaard continued, “Because of Mr. White’s extensive electrotherapy industry billing and reimbursement background, we believe he will be a good fit for our rapidly growing Zynex Medical subsidiary.”

Mr. White holds a B.A. degree in Business Management, from Bethel College.

About Zynex

Zynex, Inc. (founded in 1996), operates under three primary business segments; Zynex Medical, Zynex NeuroDiagnostics and Zynex Monitoring Solutions. Zynex Medical engineers, manufactures, markets and sells its own design of electrotherapy medical devices for standard digital electrotherapy, used for pain relief, pain management and stroke and spinal cord injury rehabilitation. Zynex Medical’s product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company’s mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex NeuroDiagnostics, currently in the development stage, has been established to market EMG, EEG, sleep pattern, auditory and nerve conductivity neurological diagnosis devices through product development or acquisitions. Zynex Monitoring Solutions, currently in the development stage, has been established to develop and market medical devices for non-invasive cardiac monitoring.

For additional information, please visit: http://www.ir-site.com/zynex/default.asp.

Safe Harbor Statement

Certain statements in this release are “forward-looking” and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2010.